The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

Study Overview
=================
Brief Summary
-----------------
Chronic obstructive pulmonary disease (COPD) is more prevalent and has more impact on health status because of progressive air pollution, tobacco smoking and aging society. The COPD prevalence investigation in 2013 by phone call showed at least 6% of the population with more than 40 years-old in Taiwan. It also was the 7th ranking of death causes in Taiwan then. Apart from chronic inflammation in lung and deteriorated lung function, it had extrapulmonary complications, such as cardiovascular problems, osteoporosis and muscle wasting. The concept of sarcopenia was proposed at first in 1989. It increases the risk of falls, disability and lowering life quality. Besides, it increased the mortality risk after admission from acute ward. Thereafter, sarcopenia is one of COPD co-morbidities, which should have great impacts of COPD. The studies showed sarcopenia reduced exercise capacities and worsening dyspnea scores. On the other hand, COPD exacerbation brings significant health burden. But there is limited data about the effect on sarcopenia on COPD exacerbation. We conducted a prospective observational study. We measured skeletal muscle mass and the strength of the used hand grip within 3 days of admission and before discharge. Mortality and exacerbation in one year are the primary end-points

Official Title
-----------------
The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

Conditions
-----------------
Sarcopenia, COPD Exacerbation

Intervention / Treatment
-----------------
* Diagnostic Test: sarcopenia measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients more than 45 years-old, were admitted due to COPD exacerbation. COPD exacerbation criteria: acute worsening respiratory symptoms without any other causes, And Smoking more than 15 pack-years or the history of noxious gas exposure, And Spirometry reports suggests obstructive ventilatory defect (FEV1/FVC <0.7) or Attending physicians diagnose as COPD by clinical parameters if spirometry data are not available while enrolling. Definite COPD exacerbation: fulfill 1、2、3 Probable COPD exacerbation: fulfill 1、2、4 Exclusion criteria: Significant fluid retention such as edema, pleural effusion or ascites, Patients with permanent pacemaker or implantable cardioverter defibrillator , Morbid obesity with BMI >34

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD exacerbation<br> | Diagnostic Test: sarcopenia measurement<br>* BIA for fat free muscle mass hand grasp strength<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality and exacerbations within 1 year of admission |  | 1 years |